Goldman Sachs Maintains Neutral on Rocket Pharmaceuticals, Lowers Price Target to $13

Benzinga · 05/09 18:11
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Neutral and lowers the price target from $15 to $13.